Synthesis and in vitro anticancer activity of 6,7-methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-one analogs
摘要:
6,7-Methylenedioxy (or 5-hydroxy-6-methoxy)-2-(substituted selenophenyl)quinolin-4-ones and their isosteric compounds were synthesized and evaluated for anticancer activity. Structure activity relationships (SAR) of these compounds were established. Among all tested compounds, 6,7-methylenedioxy-2-(5-methylselenophen-2-yl)quinolin-4-one (4d) was found to be the most promising anticancer agent. In screening against NCI's 60 human tumor cell line panel, 4d exhibited highly selective and potent inhibitory activity against MDA-MB-435 melanoma. Furthermore, the results of COMPARE analysis suggested that 4d is an antimitotic agent with a different mechanism of action from the conventional antimitotic agents, such as colchicine, vinca alkaloids and paclitaxel. Therefore, 4d was identified as a new lead compound that merits further optimization. (C) 2011 Elsevier Masson SAS. All rights reserved.
作为我们继续寻找YC-1类似物中潜在抗癌药物候选物的一部分,合成了1,3-双取代的硒代[3,2- c ]吡唑衍生物,并评估了其对NCI-H226非小细胞肺癌和非小细胞肺癌的细胞毒性。 A-498肾癌细胞系。在3-(5-羟甲基-2-呋喃基)衍生物(观察到的细胞毒性显著2,33,36和37)。其中,发现化合物2具有最有效的活性。化合物2的作用方式似乎与NCI标准数据库中列出的175种抗癌药不同,类似于YC-1。因此,我们建议化合物2 应进一步发展为治疗非小细胞肺癌和肾癌的新药候选药物。